NCT04883346View on ClinicalTrials.gov

Liraglutide (Saxenda(R)) in Adolescents With Obesity After Sleeve Gastrectomy

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 21, 2021

Primary Completion Date

March 15, 2024

Study Completion Date

April 30, 2024

Conditions
ObesityStatus Post Sleeve Gastrectomy
Interventions
DRUG

Liraglutide

Liraglutide by subcutaneous injection administered daily. Dose will be initiated at 0.6mg per day and increased to a maximum of 3.0 mg per day as tolerated.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH